Trials / Recruiting
RecruitingNCT06434597
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH5030 | SPH5030：Oral, QD, 600mg |
Timeline
- Start date
- 2024-07-17
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-05-30
- Last updated
- 2025-08-17
Locations
30 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06434597. Inclusion in this directory is not an endorsement.